Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bluebird Bio Inc (BLUE)

Bluebird Bio Inc (BLUE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 48,669
  • Shares Outstanding, K 9,792
  • Annual Sales, $ 83,810 K
  • Annual Income, $ -240,720 K
  • EBIT $ -216 M
  • EBITDA $ -155 M
  • 60-Month Beta 0.27
  • Price/Sales 0.00
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -41.00
  • Most Recent Earnings $-2.66 on 05/14/25
  • Next Earnings Date 11/19/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -1.20
  • Number of Estimates 1
  • High Estimate -1.20
  • Low Estimate -1.20
  • Prior Year -8.40
  • Growth Rate Est. (year over year) +85.71%

Most Recent Stories

More News
Bluebird: Q1 Earnings Snapshot

Bluebird: Q1 Earnings Snapshot

BLUE : 4.97 (unch)
Stocks Set to Open Sharply Lower as Tariff Worries Sour Risk Sentiment, U.S. Jobs Data and Powell’s Remarks Awaited

June S&P 500 E-Mini futures (ESM25) are down -1.01%, and June Nasdaq 100 E-Mini futures (NQM25) are down -1.21% this morning as risk sentiment took a hit ahead of U.S. President Donald Trump’s deadline...

GOOGL : 183.58 (+0.33%)
NVDA : 173.00 (+0.95%)
PVH : 71.67 (+0.36%)
OXM : 43.15 (+0.70%)
BLUE : 4.97 (unch)
WRB : 68.13 (+0.24%)
ABF.LN : 2,158.000 (+2.18%)
CAG : 18.97 (-0.37%)
LW : 50.49 (+0.98%)
ESM25 : 6,010.21s (+0.48%)
LULU : 233.31 (+3.18%)
COOP : 148.20 (+1.06%)
Bluebird: Q3 Earnings Snapshot

Bluebird: Q3 Earnings Snapshot

BLUE : 4.97 (unch)
Bluebird: Q2 Earnings Snapshot

Bluebird: Q2 Earnings Snapshot

BLUE : 4.97 (unch)
Bluebird: Q1 Earnings Snapshot

Bluebird: Q1 Earnings Snapshot

BLUE : 4.97 (unch)
Is Bluebird Bio Stock a Buy?

It won't be easy for the company to bounce back.

BLUE : 4.97 (unch)
Is Bluebird Bio Stock a Buy?

This small biotech is struggling to fly -- and investors should probably steer clear.

BLUE : 4.97 (unch)
Better Buy: Bluebird Bio Vs. Novavax

Who wins this face-to-face between two beaten-down biotechs?

BLUE : 4.97 (unch)
NVAX : 7.00 (+0.57%)
Is This Beaten-Down Stock a Good Acquisition Target?

This company has proven its innovative abilities, but that's not enough to outperform the market.

BLUE : 4.97 (unch)
Bluebird Bio Stock Has 138% Upside, According to 1 Wall Street Analyst

Biotech stocks are famously volatile. One analyst feels this one could be volatile enough to produce an outsized gain.

WFC : 79.71 (-0.25%)
BLUE : 4.97 (unch)

Business Summary

bluebird bio, Inc. is a clinical-stage biotechnology that is focused on developing gene therapies for severe genetic diseases and cancer. The company has developed a deep pipeline using lentiviral-based gene therapies, T-cell immunotherapy expertise, and gene editing capabilities to treat severe genetic...

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point N/A
1st Resistance Point N/A
Last Price 4.97
1st Support Level N/A
2nd Support Level N/A
3rd Support Level N/A

See More

52-Week High 5.03
Last Price 4.97
Fibonacci 61.8% 4.89
Fibonacci 50% 4.85
Fibonacci 38.2% 4.81
52-Week Low 4.67

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar